Jon Cuthbert

Imugene (ASX:IMU) released clinical results showing a 71% overall response rate in seven evaluable patients enrolled in Cohort 3 of its azer-cel Phase 1b trial.

The IMF has approved $138 million for El Salvador after completing two programme reviews.

Aspen Group (ASX:APZ) released its first-quarter FY27 market update, confirming it remains on track for at least 20% growth.

Anchorage Digital has cut 17% of its workforce, according to an exclusive report by The Information.

Surrozen (NASDAQ:SRZN) received U.S. FDA clearance of its investigational new drug application for SZN-8141, enabling clinical development for diabetic macular edema.

Haoxin Holdings (NASDAQ:HXHX) engaged a business broker to evaluate potential logistics acquisitions as part of its North American expansion initiative.

ACCO Brands Corporation (NYSE:ACCO) officially finalized its acquisition of Netherlands-based computer accessories provider Trust.

Moderna (NASDAQ:MRNA) shares climbed 2.2% to $193.01 premarket after Nasdaq said the vaccine maker will replace Warner Bros. Discovery (NASDAQ:WBD) in the Nasdaq-100 Index on October 9.

Manulife (NYSE:MFC) completed its previously announced long-term care reinsurance transaction with Munich American Reassurance Company, covering a policy block with C$3.2 billion of reserves.

White Energy (ASX:WEC) has agreed to acquire the entities that own the South Galilee Coal Project from AMCI Group.